[1] KUSHNER F G,HAND M,SMITH S C,et al.2009 focused updates:ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction(updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention(updating the 2005 guideline and 2007 focused update):a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Catheter Cardiovasc Interv,2009,74(7):E25-68.
[2] ABRAHAM N S,HLATKY M A,ANTMAN E M,et al.ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines:a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use[J].J Am Coll Cardiol,2010,56(24):2051-2066.
[3] KWOK C S,NIJJAR R S,LOKE Y K.Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel:systematic review and meta-analysis[J].Drug Saf,2011,34(1):47-57.
[4] YASU T,IKEE R,MIYASAKA Y,et al.Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation:a retrospective cohort study[J].Yakugaku Zasshl,2010,130(12):1743-1750.
[5] SCHMIDT M,JOHANSEN M B,ROBERTSON D J,et al.Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation[J].Aliment Pharmacol Ther,2012,35(1):165-174.
[6] BHATT D L,CRYER B L,CONTANT C F,et al.Clopidogrel with or without omeprazole in coronary artery disease[J].N Engl J Med,2010,363(20):1909-1917.
[7] ROSSINI R,CAPODANNO D,MUSUMECI G,et al.Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation[J].Coron Artery Dis,2011,22(3):199-205.
[8] AIHARA H,SATO A,TAKEYASU N,et al.Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting:results from the Lbaraki Cardiac Assessment Study Registry[J].Catheter Cardiovasc Interv,2012,80(4):556-563.
[9] GOODMAN S G,CLARE R,PIEPER K S,et al.Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor:insights from the platelet inhibition and patient outcomes trial[J].Circulation,2012,125(8):978-986.
[10] GAGLIA M A Jr,TORGUSON R,HANNA N,et al.Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes[J].Am J Cardiol,2010,105(6):833-838.
[11] BURKARD T,KAISER C A,BRUNNER-LA ROCCA H,et al.Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention:a report fromthe BASKET trial[J].J Intern Med,2012,271(3):257-263.
[12] van BOXEL O S,van OIJEN M G,HAGENAARS M P,et al.Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors:results of a large dutch cohort study[J].Am J Gastroenterol,2010,105(11):2430-2436.
[13] HSIAO F Y,MULLINS C D,WEN Y W,et al.Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome[J].Pharmacoepidemiol Drug Saf,2011,20(10):1043-1049.
[14] SADA S,COSTANTINO G.The prophylactic use of a proton pump inhibitor (PPI) in patients treated with clopidogrel and aspirin for an acute coronary syndrome or placement of a coronary stent reduces the rate of upper gastrointestinal bleeding with no apparent increase in cardiovascular events[J].Intern Emerg Med,2011,6(2):159-160.
[15] O'DONOGHUE M L,BRAUNWALD E,ANTMAN E M,et al.Pharmacodynamic effect and clinical effcacy of clopidogrel and prasugrel with or without a proton-pump inhibitor:an analysis of two randomised trials[J].Lancet,2009,374(9694):989-997.
[16] ZAIRIS M N,TSIAOUSIS G Z,PATSOURAKOS N G,et al.The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting[J].Can J Cardiol,2010,26(2):e54-57.
[17] EVANCHAN J,DONNALLY M R,BINKLEY P,et al.Recurrence of acutemyocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction[J].Clin Cardiol,2010,33(3):168-171.
[18] HO P M,MADDOX T M,WANG L,et al.Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J].JAMA,2010,301(9):937-944.
[19] CHARLOT M,AHLEHOFF O,NORGAARD M L,et al.Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use:a nationwide cohort study[J].Ann Intern Med,2010,153(6):378-386.
[20] van BOXEL O S,van OIJEN M G,HAGENAARS M P,et al.Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors:results of a large Dutch cohort study[J].Am J Gastroenterol,2010,105(11):2430-2436.
[21] HO P M,MADDOX T M,WANG L,et al.Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J].JAMA,2009,301(9):937-944.
[22] JUURLINK D N,GOMES T,KO D T,et al.A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J].CMAJ,2009,180(7):713-718.
[23] HSIAO F Y,TSAI Y W,HUANG W F,et al.A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding[J].Clin Ther,2009,31(9):2038-2047.
[24] SILLER-MATULA J M,JILMA B,SCHRÖR K,et al.Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel:a systematic review and meta-analysis[J].J Thromb Haemost,2010,8(12):2624-2641.
[25] LIMA J P,BROPHY J M.The potential interaction between clopidogrel and proton pump inhibitors:a systematic review[J].BMC Med,2010,8:81.
[26] GILARD M,ARNAUD B,CORNILY J C,et al.Infuence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin:the randomized,double-blind OCLA (omeprazole clopidogrel aspirin) study[J].J Am Coll Cardiol,2008,51(3):256-260.
[27] SILLER-MATULA J M,SPIEL A O,LANG I M,et al.Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel[J].Am Heart J,2009,157(1):148.e1-5.
[28] FERNANDO H,BASSLER N,HABERSBERGER J,et al.Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel[J].J Thromb Haemost,2011,9(8):1582-1589.
[29] FONTES-CARVALHO R,ALBUQUERQUE A,ARA AU'G JO C,et al.Omeprazole,but not pantoprazole,reduces the antiplatelet effect of clopidogrel:a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction[J].Eur J Gastroenterol Hepatol,2011,23(5):396-404.
[30] ANGIOLILLO D J,GIBSON C M,CHENG S,et al.Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects:randomized,placebo-controlled,crossover comparison studies[J].Clin Pharmacol Ther,2011,89(1):65-74.
[31] NEUBAUER H,ENGELHARDT A,KRVGER J C,et al.Pantoprazole does not infuence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting[J].J Cardiovasc Pharmacol,2010,56(1):91-97.
[32] RAY W A,MURRAY K T,GRIFFN M R,et al.Outcomes with concurrent use of clopidogrel and proton-pump inhibitors:a cohort study[J].Ann Intern Med,2010,152(6):337-345.
[33] SIMON T,STEG P G,GILARD M,et al.Clinical events as a function of proton pump inhibitor use,clopidogrel use,and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction:results from the French Registry of Acute ST-Elevation and NonST-Elevation Myocardial Infarction (FAST-MI) registry[J].Circulation,2011,123(5):474-482.
[34] KAZUI M,NISHIYA Y,ISHIZUKA T,et al.Identifcation of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J].Drug Metab Dispos,2010,38(1):92-99.
[35] CUISSET T,FRERE C,QUILICI J,et al.Comparison of omeprazole and pantoprazole infuence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study[J].J Am Coll Cardiol,2009,54(13):1149-1153.
[36] KAZUI M,NISHIYA Y,ISHIZUKA T,et al.Identifcation of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J].Drug Metab Dispos,2010,38(1):92-99.
[37] KIM K A,PARK P W,HONG S J,et al.The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel:a possible mechanism for clopidogrel resistance[J].Clin Pharmacol Ther,2008,84(2):236-242.
[38] PARK B K.Cytochrome P450 enzymes in the heart[J].Lancet,2000,355(9208):945-946.
[39] ANDERSSON T.Pharmacokinetics,metabolism and interactions of acid pump inhibitors.Focus on omeprazole,lansoprazole and pantoprazole[J].Clin Pharmacokinet,1996,31(1):9-28.
[40] LI X Q,ANDERSSON T B,AHLSTRÖM M,et al.Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole,esomeprazole,lansoprazole,pantoprazole,and rabeprazole on human cytochrome P450 activities[J].Drug Metab Dispos,2004,32(8):821-827.
[41] BLUME H,DONATH F,WARNKE A,et al.Pharmacokinetic drug interaction profiles of proton pump inhibitors[J].Drug Saf,2006,29(9):769-784.
[42] LIND T,RYDBERG L,KYLEBCK A.et al.Esomeprazole provides improved acid control vs.omeprazole in patients with symptoms of gastrooesophageal refux disease[J].Aliment Pharmacol Ther,2000,14(7):861-867.
[43] SHI S,KLOTZ U.Proton pump inhibitors:an update of their clinical use and pharmacokinetics[J].Eur J Clin Pharmacol,2008,64:935-951.
[44] BLUME H,DONATH F,WARNKE A,et al.Pharmacokinetic drug interaction profles of proton pump inhibitors[J].Drug Saf,2006,29(9):769-784. |